Towards the synthesis of novel 1,3-azaborines as potential HIV-1 protease inhibitors
Document Type
Oral Presentation
Campus where you would like to present
SURC Ballroom C/D
Start Date
16-5-2013
End Date
16-5-2013
Abstract
The considerable growth of organoboron chemistry in recent years has promoted a greater interest in the synthetic utility for boron containing compounds. Boron contains distinct chemical properties such as a dynamic coordinate system which can provide additional binding affinity, making it valuable for developing better pharmaceutical drugs. The borinic acid target compounds of this research include a chiral 1,3-azaborine, with nitrogen beta to boron. We are synthesizing novel boronates that are designed as compounds with potential dual-mode, both competitive and associative, inhibitory action of HIV-1 protease. Our target compounds provide a novel synthetic approach to produce the 1,3-azaborine structure due to the specific nature of the project. By incorporating a chiral type 1,3-azaborine into a transition state peptide mimic, we believe it will produce a medicinally significant compound. Cyclic boronates provide greater structural rigidity which are expected to be improved inhibitors than their straight chain analogs. These novel structures will also serve to expand molecular diversity and organoboron chemistry.
Recommended Citation
Sigurjonsson, Kristín, "Towards the synthesis of novel 1,3-azaborines as potential HIV-1 protease inhibitors" (2013). Symposium Of University Research and Creative Expression (SOURCE). 137.
https://digitalcommons.cwu.edu/source/2013/posters/137
Poster Number
48
Additional Mentoring Department
Chemistry
Towards the synthesis of novel 1,3-azaborines as potential HIV-1 protease inhibitors
SURC Ballroom C/D
The considerable growth of organoboron chemistry in recent years has promoted a greater interest in the synthetic utility for boron containing compounds. Boron contains distinct chemical properties such as a dynamic coordinate system which can provide additional binding affinity, making it valuable for developing better pharmaceutical drugs. The borinic acid target compounds of this research include a chiral 1,3-azaborine, with nitrogen beta to boron. We are synthesizing novel boronates that are designed as compounds with potential dual-mode, both competitive and associative, inhibitory action of HIV-1 protease. Our target compounds provide a novel synthetic approach to produce the 1,3-azaborine structure due to the specific nature of the project. By incorporating a chiral type 1,3-azaborine into a transition state peptide mimic, we believe it will produce a medicinally significant compound. Cyclic boronates provide greater structural rigidity which are expected to be improved inhibitors than their straight chain analogs. These novel structures will also serve to expand molecular diversity and organoboron chemistry.
Faculty Mentor(s)
Levente Fabry-Azstalos